 | Up a level |
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J. -U., Grischke, E. -M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2022). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study (vol 30, pg 1279, 2019). Ann. Oncol., 33 (7). S. 743 - 745. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Moebus, V., Diel, I. J., Harbeck, N., Elling, D., Jackisch, C., Thomssen, C., Untch, M., Conrad, B., Schneeweiss, A., Kreienberg, R., Huober, J., Mueller, V., Lueck, H-J, Bauerfeind, I., Loibl, S., Nekljudova, V. and von Minckwitz, G. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer 1st Interim Efficacy Analysis. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Untch, M., Fasching, P. A., Konecny, G. E., Hasmueller, S., Lebeau, A., Kreienberg, R., Camara, O., Mueller, V., du Bois, A., Kuehn, T., Stickeler, E., Harbeck, N., Hoess, C., Kahlert, S., Beck, T., Fett, W., Mehta, K., von Minckwitz, G. and Loibl, S. (2010). Pathological Complete Response after Neoadjuvant Chemotherapy plus Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
von Minckwitz, G., Kaufmann, M., Kuemmel, S., Fasching, P. A., Eiermann, W., Blohmer, J. U., Costa, S. D., Hilfrich, J., Jackisch, C., Gerber, B., Barinoff, J., Huober, J., Hanusch, C., Konecny, G., Fett, W., Stickeler, E., Harbeck, N., Mehta, K., Loibl, S. and Untch, M. (2011). Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane plus /-Trastuzumab Containing Chemotherapy. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445